Eli Lilly (LLY) Cash from Operations (QoQ) (2009 - 2026)

Eli Lilly (LLY) Cash from Operations (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 65.38%
Dec 31, 2025 -63.51%
Sep 30, 2025 186.28%
Jun 30, 2025 85.26%
Mar 31, 2025 -32.66%
Dec 31, 2024 -33.35%
Sep 30, 2024 153.16%
Jun 30, 2024 25.75%
Mar 31, 2024 473.72%
Dec 31, 2023 -114.25%
Sep 30, 2023 246.49%
Jun 30, 2023 -63.49%
Mar 31, 2023 4.08%
Dec 31, 2022 -24.99%
Sep 30, 2022 87.33%
Jun 30, 2022 -53.10%
Mar 31, 2022 11.55%
Dec 31, 2021 38.64%
Sep 30, 2021 -8.12%
Jun 30, 2021 4.60%